FDA APPROVES ACETADOTE® sNDA
FDA Approves Simplified Dosing for Life-Saving Acetaminophen Overdose Treatment
Table of Contents
- FDA Approves Simplified Dosing for Life-Saving Acetaminophen Overdose Treatment
- Cumberland Pharmaceuticals Expands Portfolio with Four New FDA-Approved Treatments
- Get Your Company’s Story Seen: PR Newswire Connects You with millions
- Breaking Barriers: Young Women Lead Charge in STEM Fields
- Acetaminophen Overdose Treatment Simplified: Expert weighs In
NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ — Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a leading specialty pharmaceutical company, announced today that the FDA has approved a supplemental New Drug Application (sNDA) for its Acetadote® (N-acetylcysteine for injection) product. this approval simplifies the governance of Acetadote, a crucial treatment for acetaminophen overdose, potentially improving patient outcomes and reducing the risk of adverse events.
acetaminophen, a common over-the-counter pain reliever, is the leading cause of acute liver failure in the United States. Thousands of individuals experience accidental or intentional acetaminophen poisoning each year, leading to serious liver damage.
the newly approved dosing regimen combines the first two bags of the standard Acetadote regimen into a single, slower infusion. This streamlined approach has been successfully implemented in hospitals worldwide and has been shown to reduce medication errors and potentially serious non-allergic anaphylactoid reactions (NAARs) without compromising the effectiveness of Acetadote.
“This FDA approval is a meaningful step forward in the treatment of acetaminophen overdose,” said Dr. Rick Dart, MD, PhD, Director at the Rocky Mountain Poison and Drug Center. “by streamlining the administration of NAC, we can improve patient outcomes and reduce the risk of adverse events. This simplified dosing regimen is a valuable tool for health care providers in managing this potentially life-threatening condition.”
“We are thrilled to announce the FDA approval of this simplified dosing regimen for Acetadote,” said A.J. Kazimi, Cumberland’s chief Executive Officer. “This critically important milestone underscores our commitment to improving patient care and providing innovative solutions for urgent medical needs. By streamlining the administration process, we aim to enhance patient outcomes and reduce the burden on health care providers.”
Key Highlights:
FDA-approved sNDA adds a simplified, IV NAC dosing regimen to the product prescribing information.
New IV NAC dosing regimen is both safe and effective.
New dosing regimen aims to minimize interruptions in care,medication errors,and the incidence of dose-related reactions.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in tennessee. the company is focused on providing unique products that improve the quality of patient care. Cumberland develops, acquires, and commercializes products for the hospital acute care, gastroenterology, and oncology market segments.
The company’s portfolio of FDA-approved brands includes:
Acetadote® (acetylcysteine) injection,for the treatment of acetaminophen poisoning;
* Caldolor® (ibuprofen) injection,for the treatment of pain and fever.
Cumberland Pharmaceuticals Expands Portfolio with Four New FDA-Approved Treatments
Nashville, TN – Cumberland Pharmaceuticals Inc. today announced the U.S. Food and Drug Administration (FDA) has approved four new products, expanding the company’s portfolio of critical care and specialty medications. These approvals mark a significant milestone for Cumberland, demonstrating its commitment to developing innovative treatments for unmet medical needs.
The newly approved medications include:
Kristalose® (lactulose) oral: A prescription laxative for the treatment of constipation.
Sancuso® (granisetron) transdermal: A patch designed to prevent nausea and vomiting in patients undergoing certain types of chemotherapy.
Vaprisol® (conivaptan) injection: An injectable medication used to increase sodium levels in hospitalized patients with specific types of low sodium conditions.
Vibativ® (telavancin) injection: An antibiotic for treating serious bacterial infections, including hospital-acquired and ventilator-associated pneumonia, as well as intricate skin and skin structure infections.
“We are thrilled to bring these important new therapies to patients and healthcare providers,” said [Insert Name and Title of Cumberland Pharmaceuticals Executive]. ”These approvals reflect our dedication to research and advancement, and our unwavering focus on improving patient outcomes.”
In addition to these new approvals, Cumberland is actively engaged in Phase II clinical trials evaluating its ifetroban product candidate for the treatment of cardiomyopathy associated with duchenne Muscular Dystrophy, Systemic Sclerosis, and Idiopathic Pulmonary Fibrosis.
For more information on Cumberland’s approved products, including full prescribing information, please visit the individual product websites, which can be found on the company’s website at www.cumberlandpharma.com.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of high-quality, patient-focused therapies. The company is committed to improving the lives of patients with unmet medical needs through innovative research and development.[Image: Cumberland Pharmaceuticals logo]
Get Your Company’s Story Seen: PR Newswire Connects You with millions
Reaching a wide audience is crucial for any business, and PR Newswire offers a powerful platform to amplify your message.
With a network spanning over 440,000 newsrooms and influencers, and distribution to more than 9,000 digital media outlets, PR Newswire puts your company’s news in front of the people who matter moast.
More Than Just Distribution
PR Newswire goes beyond simply sending out press releases.Their team of experts provides strategic guidance to help you craft compelling narratives that resonate with your target audience. From crafting attention-grabbing headlines to optimizing content for search engines, they ensure your message cuts through the noise.
Boost Your Brand visibility
Whether you’re announcing a new product launch, sharing company milestones, or responding to industry trends, PR Newswire helps you build brand awareness and establish thought leadership.Their comprehensive suite of services includes:
Press Release Distribution: Reach a vast network of journalists, bloggers, and industry professionals.
Multimedia Enhancement: Elevate your story with images, videos, and other engaging content.
Social Media Amplification: Extend the reach of your message across social media platforms.
Targeted Audience Segmentation: Ensure your news reaches the right people based on industry, location, and other demographics.Unlock the Power of PR
In today’s competitive landscape, effective communication is essential for success. PR Newswire empowers businesses of all sizes to tell their stories, connect with key stakeholders, and achieve their communication goals.
Ready to elevate your brand’s visibility?
Visit PR Newswire today and discover how their solutions can help you make a lasting impact.
Breaking Barriers: Young Women Lead Charge in STEM Fields
A new generation of female innovators is shattering stereotypes and reshaping the landscape of science, technology, engineering, and mathematics (STEM).
Across the country, young women are defying long-held assumptions and proving their prowess in traditionally male-dominated fields. From coding groundbreaking software to designing cutting-edge medical devices, these trailblazers are not only excelling in their chosen professions but also inspiring a new wave of girls to pursue STEM careers.
“Growing up, I never saw many women in STEM roles,” says 22-year-old Maya Rodriguez, a recent graduate with a degree in aerospace engineering. “But that just fueled my determination to break down those barriers. I want to show young girls that anything is possible.”
Rodriguez is now working at a leading aerospace company, contributing to the development of sustainable aviation technologies. Her story is just one of many.
Universities and tech companies are witnessing a surge in female enrollment and participation in STEM programs. initiatives aimed at encouraging girls’ interest in science and technology from a young age are gaining momentum, fostering a supportive surroundings for future generations.
“We’re seeing a real shift in mindset,” says Dr. Emily Chen, a professor of computer science at a prominent university. “More and more girls are realizing that STEM fields are not just for boys. They’re discovering the exciting possibilities and the impact they can make through innovation.”
The rise of female role models in STEM is also playing a crucial role in inspiring young girls. From astronauts to entrepreneurs, these women are demonstrating that success in STEM is attainable for anyone with passion and dedication.
While challenges remain, the progress made in recent years is undeniable. As more young women break through the glass ceiling in STEM, they are paving the way for a more diverse and inclusive future, were innovation knows no gender boundaries.
Acetaminophen Overdose Treatment Simplified: Expert weighs In
NewsDirectory3.com – A recent FDA approval for Cumberland Pharmaceuticals’ Acetadote® (N-acetylcysteine) offers a ray of hope for victims of acetaminophen overdose, a leading cause of acute liver failure in the US. this simplified dosing regimen promises to streamline treatment, potentially improving patient outcomes and minimizing the risk of adverse events.
We spoke to Dr. Rick Dart, MD, PhD, Director at the Rocky Mountain Poison and drug Center, to understand the meaning of this progress.
NewsDirectory3: Dr.Dart, what are the key implications of this new streamlined dosing regimen for Acetadote?
Dr. Dart: This approval is a significant step forward in the management of acetaminophen overdose. For years, the standard treatment involved administering multiple IV bags of N-acetylcysteine according to a specific schedule. This process, while effective, could be complex and prone to errors, particularly in busy hospital settings.
The new regimen combines the initial two bags into a single, slower infusion, which simplifies administration significantly. This simplifies the process for healthcare providers, reducing the risk of medication errors and ultimately leading to safer and timelier treatment.
NewsDirectory3: You mentioned the importance of minimizing errors. Can you elaborate on the potential risks associated with the previous dosing method?
Dr. Dart: While Acetadote is a vital life-saving medication, it can be associated with side effects like non-allergic anaphylactoid reactions (naars). These reactions, while rare, can be serious.
By streamlining the dosing process, we hope to minimize the risk of these reactions occurring, while still ensuring patients receive the full therapeutic benefit of Acetadote.
NewsDirectory3: Beyond patient safety, how else might this simplified dosing regimen benefit patients?
Dr. Dart: By making the administration process more efficient, we can potentially reduce interruptions in care. Faster treatment also affords patients a quicker path to recovery.
Furthermore, the clarity and simplicity of this new dosing regimen empowers healthcare providers to effectively manage these critical situations, leading to improved outcomes for patients with acetaminophen toxicity.
This FDA approval underscores Cumberland Pharmaceuticals’ commitment to innovation and patient care. It represents a tangible step towards addressing a significant public health issue and offers hope to countless individuals at risk of acetaminophen overdose.